journal article·2024-02-07

Engineering Nanosensitizer to Remodel the TME for Hypoimmunogenic “Cold”–“Hot” Tumor Transformations

Zhongqing Liu, Ziqi Wang, Zhishuai Zhang, Zhenwei Zhang, Xin Qi, Hanwen Zhu, Kuo Zhang, Tianrui Qu, Yubo Zhao, Zhijian Kang, Fanshu Zeng, Pengyu Guo, Zhichao Tong, Lu Wang, Hao Wang, Wanhai Xu

Nano Letters· Volume 24· Issue 5
Publisher page

Abstract

α-PD-L1 therapy has shown encouraging results at harnessing the immune system to combat cancer. However, the treatment effect is relatively low due to the dense extracellular matrix (ECM) and tumor immunosuppressive microenvironment (TIME). Therefore, an ultrasound (US)-responsive nanosensitizer (URNS) is engineered to deliver losartan (LST) and polyethylenimine (PEI) to remolde the TME, driving “cold”–“hot” tumor transformation and enhancing the sensitivity of α-PD-L1 therapy. In the tumor site, noninvasive US can make MTNP generate ROS, which cleave ROS-sensitive bonds to dissociate MTNP tK @LST-PEI, shedding PEI and releasing LST from mesoporous spheres. The results demonstrated that URNS combined with α-PD-L1 therapy effectively inhibited tumor growth with an inhibition rate as high as 90%, which was 1.7-fold higher than that of the α-PD-L1 treatment in vivo . In summary, the URNS improves the sensitivity of α-PD-L1 therapy by remodeling the TME, which provides promising insights for optimizing cancer immunotherapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer Immunotherapy and Biomarkers · Cancer Research and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

NHC Key Laboratory of Molecular Probes and Targeted Diagnosis and Therapy, Harbin Medical University, Harbin 150001, People’s Republic of China

Harbin Medical University, Harbin 150001, People’s Republic of China

Department of Urology, The First Affiliated Hospital of Shandong First Medical University & Shandong Province Qianfoshan Hospital, Jinan 250014, People’s Republic of China

Department of Urology (Heilongjiang Key Laboratory of Scientific Research in Urology), Harbin Medical University Cancer Hospital, Harbin 150001, People’s Republic of China

CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology (NCNST), Beijing 100190, People’s Republic of China

Funding

National Key Research and Development Program of China · China Postdoctoral Science Foundation · Harbin Medical University · Heilongjiang Provincial Postdoctoral Science Foundation · National Natural Science Foundation of China · University Nurising Program for Young Scholar with Creative Talents in Heilongjiang Province

References (51)

Show source-provided references
1. 10.1016/j.cell.2017.10.02710.1016/j.cell.2017.10.027 ↗
2. 10.1056/NEJMoa130236910.1056/NEJMoa1302369 ↗
3. 10.1038/s41565-021-01032-w10.1038/s41565-021-01032-w ↗
4. 10.1038/s41467-019-12771-910.1038/s41467-019-12771-9 ↗
5. 10.1126/sciimmunol.aau658410.1126/sciimmunol.aau6584 ↗
6. 10.1126/scitranslmed.aad711810.1126/scitranslmed.aad7118 ↗
7. 10.1126/science.aaa817210.1126/science.aaa8172 ↗
8. 10.1038/nnano.2017.6910.1038/nnano.2017.69 ↗
9. 10.1038/nnano.2017.5710.1038/nnano.2017.57 ↗
10. 10.1073/pnas.201129711710.1073/pnas.2011297117 ↗
11. 10.1136/bmj.k352910.1136/bmj.k3529 ↗
12. 10.1038/nature1401110.1038/nature14011 ↗
13. 10.1002/adma.20200600310.1002/adma.202006003 ↗
14. 10.1038/s41565-021-01032-w10.1038/s41565-021-01032-w ↗
15. 10.1021/acs.accounts.9b0014810.1021/acs.accounts.9b00148 ↗
16. 10.1016/j.semcancer.2019.11.01010.1016/j.semcancer.2019.11.010 ↗
17. 10.1002/adfm.20200754410.1002/adfm.202007544 ↗
18. 10.1039/C6CS00592F10.1039/C6CS00592F ↗
19. 10.1038/s41565-018-0319-410.1038/s41565-018-0319-4 ↗
20. 10.1038/s41551-018-0236-810.1038/s41551-018-0236-8 ↗
21. 10.1002/adma.20210826310.1002/adma.202108263 ↗
22. 10.1002/adma.20190499710.1002/adma.201904997 ↗
23. 10.1038/nnano.2016.16810.1038/nnano.2016.168 ↗
24. 10.1002/adma.20200205410.1002/adma.202002054 ↗
25. 10.1002/adma.20200618910.1002/adma.202006189 ↗
26. 10.1021/acsnano.1c0995910.1021/acsnano.1c09959 ↗
27. 10.1038/s41557-020-00624-810.1038/s41557-020-00624-8 ↗
28. 10.1038/nmat285910.1038/nmat2859 ↗
29. 10.1002/adfm.20190859810.1002/adfm.201908598 ↗
30. 10.1002/adma.20200521510.1002/adma.202005215 ↗
31. 10.1038/ncomms351610.1038/ncomms3516 ↗
32. 10.1073/pnas.101889210810.1073/pnas.1018892108 ↗
33. 10.1186/s12951-021-01073-210.1186/s12951-021-01073-2 ↗
34. 10.1016/j.biomaterials.2012.09.06210.1016/j.biomaterials.2012.09.062 ↗
35. 10.1016/j.biomaterials.2015.02.06810.1016/j.biomaterials.2015.02.068 ↗
36. 10.1038/nmat285910.1038/nmat2859 ↗
37. 10.1002/anie.20120963310.1002/anie.201209633 ↗
38. 10.1021/jacs.7b1202510.1021/jacs.7b12025 ↗
39. 10.1039/c2cs15330k10.1039/c2cs15330k ↗
40. 10.1002/adma.20210464110.1002/adma.202104641 ↗
41. 10.1002/anie.20210270310.1002/anie.202102703 ↗
42. 10.1021/acs.chemrev.7b0016110.1021/acs.chemrev.7b00161 ↗
43. 10.1002/adma.20210033310.1002/adma.202100333 ↗
44. 10.1002/anie.20120963310.1002/anie.201209633 ↗
45. 10.1021/acsnano.2c1216510.1021/acsnano.2c12165 ↗
46. 10.1038/s41467-023-41946-810.1038/s41467-023-41946-8 ↗
47. 10.1002/adma.20170014110.1002/adma.201700141 ↗
48. 10.1021/jacs.8b0772710.1021/jacs.8b07727 ↗
49. 10.1021/acsnano.7b0821910.1021/acsnano.7b08219 ↗
50. 10.1002/adma.20200485310.1002/adma.202004853 ↗
51. 10.1002/adfm.20210612310.1002/adfm.202106123 ↗